2019
Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes
Zambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Stang MT, Roman SA, Sosa JA, Scheri RP. Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes. Surgery 2019, 166: 895-900. PMID: 31288935, PMCID: PMC6802283, DOI: 10.1016/j.surg.2019.05.035.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerLow-risk papillary thyroid cancerEmergency department visitsShort-term outcomesTotal thyroidectomyThyroid cancerFemale patientsBlack patientsEnd Results-Medicare databaseMore emergency department visitsLow-risk thyroid cancerExtent of thyroidectomyExtent of surgeryMultivariable logistic regressionUnderwent lobectomyUnplanned readmissionOlder patientsAvoidable complicationsMean ageMorbidity increasesThyroidectomyPatientsReadmissionComplicationsLobectomy
2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapyMinimally Invasive Versus Open Pancreaticoduodenectomy for Cancer
Adam MA, Choudhury K, Dinan MA, Reed SD, Scheri RP, Blazer DG, Roman SA, Sosa JA. Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer. Annals Of Surgery 2015, 262: 372-377. PMID: 26158612, DOI: 10.1097/sla.0000000000001055.Peer-Reviewed Original ResearchConceptsShort-term outcomesOpen pancreaticoduodenectomyMajority of hospitalsOpen surgeryInvasive Versus Open PancreaticoduodenectomyNational practice patternsSingle institutional experiencePositive surgical marginsLength of stayNeuroendocrine tumor diagnosisMultivariable adjustmentAdult patientsLymph nodesSurgical marginsInvasive pancreaticoduodenectomyOpen procedurePractice patternsInstitutional experiencePancreaticoduodenectomyMultivariable modelingMortality ratePatientsPatient safetyMIPDTumor diagnosisInitial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGuideline AdherenceHealthcare DisparitiesHumansMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypePractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsRacial GroupsResidence CharacteristicsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsIntermediate-risk diseaseBreast cancerRecurrence scoreClinical practiceNode-negative breast cancerNational Comprehensive Cancer NetworkAdjuvant chemotherapy useIncident breast cancerComprehensive Cancer NetworkEnd Results (SEER) dataHigh-grade diseaseRetrospective observational studyRoutine clinical practiceTumor histologic characteristicsMedicare coverage decisionsAdjuvant chemotherapyChemotherapy useN1 diseaseMost patientsComorbid conditionsMultivariable analysisRS assayClinical variablesStudy criteriaBlack race
2009
Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures
Dinan MA, Chou C, Hammill BG, Graham FL, Schulman KA, Telen MJ, Reed SD. Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures. American Journal Of Hematology 2009, 84: 703-709. PMID: 19787790, PMCID: PMC2783350, DOI: 10.1002/ajh.21520.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh-volume surgical proceduresHip replacementMedian ageInpatient costsCell diseaseSurgical proceduresClinical Classification Software codesMore health care resourcesLonger hospital stayHigher inpatient costsNationwide Inpatient SampleLength of stayMultivariable regression analysisHealth care resourcesRegression analysisHospital mortalityHospital stayInpatient outcomesInpatient mortalitySurgical patientsInpatient staySCD cohortInpatient SampleProcedural characteristics